A phase 2 study of Azercabtagene zapreleucel in CAR T Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
Latest Information Update: 22 Aug 2023
At a glance
- Drugs Azercabtagene zapreleucel (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
Most Recent Events
- 15 Aug 2023 According to a Precision BioSciences media release, the company announced completion of a strategic transaction with Imugene Limited for global rights to Azercabtagene Zapreleucel (azer-cel). Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population who have relapsed following autologous CAR T treatment.
- 27 Jul 2023 According to a Precision BioSciences media release, the company has received final meeting minutes from its recent Type B End of Phase 1 meeting with the U.S. Food and Drug Administration (FDA) to gain further clarity on the potential registration path for azer-cel including study design, endpoints and the recommended phase 2 dose for the CAR T relapsed patient setting.
- 06 Jun 2023 New trial record